Cemiplimab

Trade Name: 
Libtayo
Manufacturer/Distributor: 
Sanofi-aventis Canada Inc.
Classification: 
Antineoplastic agent
Monoclonal antibody
ATC Class: 
L01XC33 - cemiplimab
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2019/04/10 (NOC/C)
Date Marketed in Canada (yyyy/mm/dd): 
2019/05/24
Presentation: 
Injection: 250 mg/5 mL. DIN: 02487152
Injection: 350 mg/7 mL. DIN: 02487144
Comments: 
For treatment of adults with squamous call carcinoma. NOC/C issued pending results of trials to verify clinical benefit.